Armistice Capital, Llc Acquires 33,292 Shares of Cerecor Inc (CERC) Stock

Cerecor Inc (NASDAQ:CERC) Director Armistice Capital, Llc acquired 33,292 shares of the business’s stock in a transaction dated Monday, October 29th. The stock was purchased at an average price of $3.94 per share, with a total value of $131,170.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Armistice Capital, Llc also recently made the following trade(s):

  • On Friday, October 26th, Armistice Capital, Llc acquired 55,899 shares of Cerecor stock. The stock was purchased at an average price of $3.94 per share, with a total value of $220,242.06.
  • On Wednesday, October 24th, Armistice Capital, Llc acquired 83,800 shares of Cerecor stock. The stock was purchased at an average price of $4.06 per share, with a total value of $340,228.00.
  • On Monday, October 22nd, Armistice Capital, Llc acquired 20,000 shares of Cerecor stock. The stock was purchased at an average price of $4.31 per share, with a total value of $86,200.00.
  • On Monday, October 8th, Armistice Capital, Llc bought 19,588 shares of Cerecor stock. The stock was bought at an average cost of $4.33 per share, with a total value of $84,816.04.
  • On Thursday, October 4th, Armistice Capital, Llc bought 2,015 shares of Cerecor stock. The stock was bought at an average cost of $4.35 per share, with a total value of $8,765.25.
  • On Thursday, September 27th, Armistice Capital, Llc bought 6,473 shares of Cerecor stock. The stock was bought at an average cost of $4.71 per share, with a total value of $30,487.83.
  • On Tuesday, September 25th, Armistice Capital, Llc bought 9,296 shares of Cerecor stock. The stock was bought at an average cost of $4.60 per share, with a total value of $42,761.60.

NASDAQ CERC opened at $3.78 on Wednesday. Cerecor Inc has a 1-year low of $1.00 and a 1-year high of $5.74. The company has a debt-to-equity ratio of 0.75, a current ratio of 0.62 and a quick ratio of 0.54. The stock has a market capitalization of $160.28 million, a PE ratio of 9.00 and a beta of 1.33.



Cerecor (NASDAQ:CERC) last released its earnings results on Thursday, August 9th. The company reported ($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.10). Cerecor had a return on equity of 43.87% and a net margin of 15.71%. The company had revenue of $4.79 million during the quarter, compared to analyst estimates of $4.50 million. Equities research analysts forecast that Cerecor Inc will post -0.55 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp lifted its stake in shares of Cerecor by 182.0% in the 1st quarter. Northern Trust Corp now owns 31,506 shares of the company’s stock valued at $135,000 after acquiring an additional 20,333 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Cerecor by 630.4% in the 2nd quarter. BlackRock Inc. now owns 27,520 shares of the company’s stock valued at $120,000 after acquiring an additional 23,752 shares during the last quarter. Finally, Spark Investment Management LLC bought a new stake in shares of Cerecor in the 2nd quarter valued at about $288,000. 41.59% of the stock is owned by institutional investors.

Separately, ValuEngine raised Cerecor from a “hold” rating to a “buy” rating in a research note on Wednesday, August 29th.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.

Featured Story: The benefits and drawbacks of dollar cost averaging

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply